p73 is a novel gene that has high sequence homology and similar gene structure to the tumor suppressor gene p53. We analysed p73 in seven ovarian carcinoma cell lines and a total of 63 human borderline and invasive ovarian tumor samples. Loss of heterozygosity at this locus was observed in 50% of invasive tumors but in none of the borderline tumors. Biallelic expression of the gene was observed in the heterozygous tumor tissues. Direct sequencing and single-strand conformation polymorphism analyses of the p73 cDNA sequence homologous to the highly mutatable region of p53 did not reveal any mutations. When compared to the primary cultures of normal human ovarian surface epithelial cells and immortalized cell lines, four of the seven ovarian carcinoma cell lines, 71% of the invasive tumors, and 92% of the borderline tumor tissues express elevated levels of p73 transcript. Except for the OVCA3 cell line, Western blot analysis of the nuclear extracts prepared from the cell lines showed concordant levels of p73 protein. Our analysis also demonstrated the expression of a spliced variant of p73 transcript with the omission of exon 2 solely in the cancer cell lines and invasive tumor tissues. This exon 2-spliced transcript would give rise to a truncated p73 protein without the N-terminal transactivation domain. In reminiscence of the dominant negative phenotype of the N-terminal truncated variants of another p53-related gene, p63, the expression of the truncated p73 variant form in ovarian tumors may play an important role in the pathogenesis of ovarian cancer.
p73 is a novel gene that has high sequence homology and similar gene structure to the tumor suppressor gene p53. We analysed p73 in seven ovarian carcinoma cell lines and a total of 63 human borderline and invasive ovarian tumor samples. Loss of heterozygosity at this locus was observed in 50% of invasive tumors but in none of the borderline tumors. Biallelic expression of the gene was observed in the heterozygous tumor tissues. Direct sequencing and single-strand conformation polymorphism analyses of the p73 cDNA sequence homologous to the highly mutatable region of p53 did not reveal any mutations. When compared to the primary cultures of normal human ovarian surface epithelial cells and immortalized cell lines, four of the seven ovarian carcinoma cell lines, 71% of the invasive tumors, and 92% of the borderline tumor tissues express elevated levels of p73 transcript. Except for the OVCA3 cell line, Western blot analysis of the nuclear extracts prepared from the cell lines showed concordant levels of p73 protein. Our analysis also demonstrated the expression of a spliced variant of p73 transcript with the omission of exon 2 solely in the cancer cell lines and invasive tumor tissues. This exon 2-spliced transcript would give rise to a truncated p73 protein without the N-terminal transactivation domain. In reminiscence of the dominantIntroduction p73 is the ®rst identi®ed gene encoding a protein that demonstrates remarkable sequence similarity to the DNA-binding (63% identity), transactivation (29% identity), and oligomerization (38% identity) domains of the tumor suppressor protein p53 (Kaghad et al., 1997) . When overexpressed, p73 was shown to interact with p53; suppress focus formation in SK-N-AS neuroblastoma cells and Saos-2 osteosarcoma cells; activate p53-responsive gene p21
waf ; and induce apoptosis in transformed Saos-2 and Baby Hamster Kidney cells (Kaghad et al., 1997; Jost et al., 1997) . In addition, p73 was found to be monoallelically expressed in a neuroblastoma cell line and peripheral blood cells of normal donors (Kaghad et al., 1997) . However, unlike p53, the expression of p73 is not activated by chemical or radiation-mediated DNA damages (Kaghad et al., 1997) . In addition, several recent studies of p73 in human solid tumors did not reveal any signi®cant somatic mutations in the gene itself (Nomoto et al., 1998; Mai et al., 1998; Takahashi et al., 1998; Kovalev et al., 1998) , raising the doubt whether p73 has any important role in the pathogenesis of human cancer.
The chromosomal localization of p73 is at 1p36.33 (Kaghad et al., 1997) , a region which in many cytogenetic studies shows high frequency of abnormalities in ovarian cancer (Pejovic, 1995; Thompson et al., 1997) . Human carcinogenesis is believed to be a multistage process involving somatic activation of protooncogenes and inactivation of tumor suppressor genes and other less de®ned genetic alterations. Some of these genetic alterations have been described for human epithelial ovarian cancers (Mok et al., 1993; Wertheim et al., 1994; Fajac et al., 1995) . Our previous and current studies on invasive and borderline ovarian tumors have indicated that p53 inactivation appears to be the most frequent genetic change in ovarian cancer (Wertheim et al., 1994) . In order to evaluate possible involvement of p73 in the pathogenesis of ovarian cancer and any association of p73 and p53 gene status in ovarian cancer, we have analysed seven ovarian carcinoma cell lines and a total of 63 human invasive and borderline ovarian tumor samples for any allelic loss, mutations, and dierence in allelic expression of the p73 gene. The results obtained were also analysed together with the p53 gene status of the tumor samples.
Results and Discussion
We ®rst investigated if there was allelic loss at the p73 locus in our tumor samples (Figure 1a) . Analysis of p73 transcripts in neuroblastoma cell lines has discovered an allelic polymorphism consisting of a double nucleotide substitutions (G?A) and (C?T) at positions 4 and 14, respectively, within the 5'-untranslated region (Kaghad et al., 1997) . The two distinct alleles can be distinguished by PCR ± SSCP analysis of the genomic DNA derived from paired tumor and normal ovarian tissues as described in Materials and methods. Of all the 32 cases of invasive tumors and 11 cases of borderline tumors examined, only one case of AT homozygosity was found for each tumor form. Predominance of GC homozygosity over AT homozygosity has also been observed in tissues and cell lines of other tumor types (Kaghad et al., 1997; Nomoto et al., 1998; Mai et al., 1998) . LOH was observed in ®ve of the 10 informative cases of invasive tumor. Four of the ®ve LOH cases have lost the AT allele. Interestingly, no LOH was observed in all of the ®ve informative cases of borderline tumor.
Frequent LOH at the p73 locus in invasive ovarian tumors has led us to investigate whether the p73 gene itself is altered in ovarian cancer. Southern blot analysis of 20 invasive tumors and six borderline tumors did not reveal any gross genomic alterations of p73 (data not shown). To further pursue if there were any mutations in the functionally important domains of p73, we have examined the RT ± PCR products derived from the tumor RNAs by direct sequencing and single-strand conformation polymorphism (SSCP) for any mutations in the p73 cDNA sequence that is homologous to the DNA binding region of the p53 protein. This part of the p73 cDNA sequence has the highest homology to p53 (63% identity) and encompasses consensus residues corresponding to those of p53 sequence which are frequently mutated in tumors (Coles et al., 1992; Frankel et al., 1992; Kaghad et al., 1997) . The analysis of PCR products did not reveal any detectable mutations from the tumor cDNAs (data not shown).
Monoallelical expression of p73 was reported in an analysis of lymphocytes from ®ve heterozygous donors and one neuroblastoma cell line by Kaghad et al. (1997) . To evaluate if monoallelical expression of p73 exists in ovarian cancer, RT ± PCR was performed with RNAs from heterozygous tumors to amplify 5'-cDNA fragments containing the polymorphic region. Direct sequencing of the ampli®ed fragments ( Figure 1b ) demonstrated biallelic expression of p73 in the heterozygous tumors. Quantitative RT ± PCR did not reveal any reduction of p73 expression in the LOH cases (data not shown). Hence, it is unlikely that p73 is inactivated in ovarian tumors by the conventional twohit mechanism for the loss of function of tumor suppressor genes or genomic imprinting.
RT ± PCR was also used to examine the expression levels of p73 in ovarian tumor cell lines and tissues ( Figure 2 ). In comparison with four human normal ovarian surface epithelial (HOSE) primary cultures and two immortalized HOSE cell lines, four of the six cancer cell lines, 71% (27 of 38 cases) of the invasive ovarian tumors, and 92% (11 of 12 cases) of the borderline tumors demonstrated overexpression of p73 transcript. Notably, in addition to the 344 bp wild-type 5'-cDNA PCR fragment, a smaller fragment was observed in many of the tumor tissues and cancer cell lines. This smaller fragment was particularly abundant in the invasive cancer cell lines and tumor tissues. In some cases, the levels of the smaller transcript were similar to those of the wild-type p73 transcript (see lanes 10 and 15 in Figure 2b ). In contrast, no detectable p73 transcript of this size was seen in the normal HOSE primary cultures and immortalized HOSE cell lines. Sequencing of this smaller transcript revealed the reported 5'-cDNA sequence of p73 with a splicing of exon 2 (Figure 3a) . Omission of exon 2 would delete the ®rst 48 residues from the wild-type p73 protein. Translation of the truncated protein will start from a downstream in-frame ATG initiation 327, 334, 339, 341, 357, 382, 398, 428, 434, and 582 . M is the pBluescript SK + HpaII digest DNA marker, the positions of the wild-type and exon 2-deleted fragments are indicated by arrows. The RT ± PCR reactions for GAPDH are shown at the bottom of both panels protein and a recently identi®ed p53-related p63 protein (Schmale and Bamberger, 1997; Osada et al., 1998; Trink et al., 1998; Yang et al., 1998) .
To evaluate the expression of p73 protein, we performed Western blot analysis of the nuclear lysates prepared from the ovarian cell lines using a p73-speci®c polyclonal antibody (Figure 4a ). The p73 antibody detected a single band in the lysates of CAOV3, OVCA429, and OVCA433 cells. Although abundant p73 transcript was observed in the OVCA3 cells (Figure 2a) , Western blot analysis did not reveal any p73 protein expression. Whether it is due to posttranscriptional regulation of p73 expression remains to be determined. Most strikingly, the mobilities of the wild-type p73 and exon 2-deletion p73 control proteins were the same as detected by Western blot. One plausible explanation is that the calculated molecular weights of the wild-type p73 and its exon 2-deleted variant dier by only 4 kDa and the two polypeptides have dierent estimated isoelectric points (6.5 for the wild-type protein versus 7.64 for the exon 2-deleted variant). Therefore they have similar mobility on the polyacrylamide gel. Based on the expression of the two transcripts as seen in RT ± PCR, expression of the truncated p73 protein was anticipated in the cancer cell lysates. No signal for p73 was seen in the lysates prepared from immortalized normal ovarian epithelial cells. Western blot analysis of the lysates with a p53-speci®c antibody revealed a dierent pattern, demonstrating that there was no cross-reaction of the p73 Figure 4 Expression of p53 and p73 in ovarian cancer cells. (a) Western blot analysis of the nuclear lysates prepared from the ovarian cell lines using a p73-speci®c antibody. The wild-type and exon 2-deleted variant controls were lysates prepared from the respective p73 cDNA transfectants as described in Materials and methods. HOSE 1 ± 15 and HOSE 11 were two immortalized normal ovarian epithelial cell lines. The other ®ve lysates were prepared from ovarian carcinoma cell lines. Molecular weight marker is shown on the left. For comparison, the expression of p53 proteins in the lysates was also analysed and shown. The staining of nuclear protein PCNA was used as loading control. (b) Analysis of p73 and p53 expression in ovarian cancer cell lines and tissues. a Data extracted from Yaginuma et al. (1992) and Wertheim et al. (1994) . N.D., not determined. term., termination of the open reading frame p73 in ovarian cancer S-W Ng et al antibody to p53. Taken together, the results of Western blot analysis are mostly consistent with the RT ± PCR results. Our results showed biallelic and elevated p73 expression in ovarian cancer cell lines and tumor tissues. Similar observations have also been found in human bladder cancer and other human cancers (Kovalev et al., 1998; Yokomizo et al., 1999) . As p73 shows remarkable amino acid sequence and functional similarities to p53, overexpression of p73 may be a compensatory or a deleterious upregulation for the disruption of normal p53 function. We summarized our p73 expression data for those ovarian cancer cell lines and tissues with known p53 gene status in Figure  4b . No simple correlation was found between p53 mutations and overexpression with the expression levels of p73. High levels of p73 expression were also observed in tumor tissues with wild-type p53 gene status. Hence, the mechanism that upregulates the expression of p73 in ovarian tumors may be independent of or not responsive to the gene status of p53. Indeed, many recent studies have indicated that the signaling and regulatory roles of p73, or of the second p53-related gene, p63, are dierent from those of p53 (Shimada et al., 1999; Hagiwara et al., 1999; Davison et al., 1999) . Only a subset of viral oncoproteins that antagonizes p53 function also interacts with p73 (Marin et al., 1998; Higashino et al., 1998) . The oligomerization domains of p63 and p73 are able to weakly associate with one another in vitro, while the oligomerization domain of p53 does not associate with that of either p73 or p63 (Davison et al., 1999) . Threedimensional solution structure of the C-terminal domain of human p73 reveals a small ®ve-helix bundle that is absent in the C-terminus of p53, but with striking similarity to the SAM domain, a putative protein-protein interaction domain found in a variety of cytoplasmic signaling proteins. It suggests that p73 may also interact to other uncharacterized proteins which are distinct from the p53 pathway (Chi et al., 1999) .
Our RT ± PCR results indicate that there is expression of an exon 2-deleted p73 variant transcript in most of the cancer cell lines and tumor tissues. It is intriguing that the other p53-related gene, p63, was also found by RT ± PCR to express transcripts that encode N-terminal truncated p63 . Cotransfection experiments have shown that the Nterminal truncated p63 form can transdominantly suppress the transactivation functions of wild-type p53 or a full-length p63 . It is tempting to postulate that an N-terminal truncated p73 variant may likewise exhibit similar negative function. Within the putative transactivation domain that is absent in the truncated p73 protein, a sequence TFEHLW is similar to the MDM2-binding domain (TFSDLW) of p53 (Figure 3c ). Binding of p53 by MDM2 can result in enhanced degradation of p53 and repression of p53-speci®c transcription (Kubbutat et al., 1997; Thut et al., 1997) . Recently, it has been shown that MDM2 can bind to and inhibit the transcriptional activation function of p73, without promoting p73 degradation (Zeng et al., 1999; Dobbelstein et al., 1999) . It is interesting to study whether the p73 truncated form interacts dierently to MDM2 and other components of the transcriptional complex. Whether the truncated form, like the Nterminal truncated forms of p63, can transdominantly suppress the transactivation function of the full-length p73 and contribute to the pathogenesis of ovarian cancer awaits further investigation.
Materials and methods

Cell lines and tumor tissues
The primary human ovarian surface epithelial (HOSE) cells were established in this laboratory as described before (Mok et al., 1995) . Immortalized cells were obtained by infecting the HOSE cells with a replication-defective retroviral construct, LXSN16E6E7, as described (Mok et al., 1995) . The tumor cell lines OVCA420, OVCA429, OVCA432, OVCA433 were established in this laboratory (Mok et al., 1995) . CAOV3 and SKOV3 were obtained from American Type Culture Collection (ATCC); and the OVCA3 cell line was obtained from the National Cancer Institute. All the ovarian cell lines were cultured in Medium 199 and MCDB 105 (1 : 1) supplemented with 10% fetal calf serum. Ovarian tumors, along with uninvolved ovarian tissues where available, were obtained from patients at the Brigham and Women's Hospital in Boston as described previously (Mok et al., 1995) . All tumor tissues (44 invasive carcinomas and 19 cases of borderline tumors) were collected from the primary ovarian sites and were con®rmed histologically. All the surgical specimens were collected with patients consents.
LOH study by PCR ± SSCP analysis
To analyse the two distinct alleles of p73, PCR ampli®cation was carried out using genomic DNA in the presence of [a-32 P]dCTP, followed by SSCP on 6% nondenaturing polyacrylamide gels with 5% glycerol at room temperature. The primer pair (5'-CAGGCCCACTTGCCTGCC-3' and 5'-AGAGGTGCTCAAACGTGG-3') and PCR condition was according to Nomoto et al. (1998) with minor modi®cation (948C for 10 min, and then 35 cycles of 948C for 1 min, 558C for 1 min, 728C for 1 min). Tumor samples were scored as having LOH when the signal intensity was decreased by more than 50%.
Mutational analysis by SSCP
PCR was performed from RT ± cDNA using the primer set 1: 5'-ATGTCGCCGGCGCCTGTC-3' and 5'-AGCAGACTGT-CCTTCGTTGAA-3'; and primer set 2: 5'-AACCACGAGC-TCGGGAGG-3' and 5'-CCGGTAGTGGTCCTCATC-3'. These two primer sets cover 606 bp of the p73 cDNA sequence including the region most homologous to the p53 DNA-binding region (Kaghad et al., 1997) . The PCR conditions were: 948C for 30 s, 608C for 1 min (568C for primer set 2), and 728C for 1 min for 35 cycles. [a-32 P]dCTP was incorporated during the last ®ve cycles. SSCP was performed at room temperature on a 6% nondenaturing polyacrylamide gel containing 5% glycerol.
RT ± PCR and sequencing
RT was performed with 5 mg of total RNA, random hexamers, and reverse transcriptase (Perkin-Elmer Corp.). The PCR primers for p73 were 5'-ACGCAGCGAAACCGG-GGCCCG-3' and 5'-GCCGCGCGGCTGCTCATCTGG-3'. For quantitative purpose, PCR reactions were performed using AmpliTaq Gold and 9600 PCR thermal cycler (PerkinElmer Corp.) under the following conditions: 948C for 10 min for activation of AmpliTaq, followed by 948C for 30 s, 728C for 2 min for 25 cycles with [a- 
Western blot analysis
Cells were harvested and lysed in buer A (10 mM HEPES, pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM DTT) containing 0.5% NP-40. Nuclei were washed, further lysed by buer B (20 mM Tris, pH 7.5, 100 mM NaCl, 50 mM KCl, 0.1 mM EDTA, 0.1 mM PMSF, 0.2% NP-40, 0.1% Triton X-100, 1% SDS, 10% glycerol). The lysates were depleted of DNA by ultracentrifugation. Protein determination was performed by Micro-BCA kit (Pierce Corp.). About 20 mg of nuclear lysates were electrophoresed on a 10% polyacrylamide gel. The proteins were transferred to PVDF membrane and probed with antibodies. The polyclonal p73 antibody has been described elsewhere (Kaghad et al., 1997) and was kindly provided by Dr Frank McKeon. The p53 (Pab 1801) and PCNA antibodies were purchased from Oncogene Research Products. The p73 wild-type and exon 2-deletion controls were cell lysates prepared from COS7 cells transfected with the respective expression constructs. For the cloning of p73 wild-type and exon 2-deletion expression constructs, 5'-end cDNA fragments containing wild-type and exon 2-deletion sequences were ampli®ed from OVCA429 RT product using primers 5'-ACGCAGCGAAACCGGGGCCCG-3' and 5'-CCGGTAGTGGTCCTCATC-3'. 3'-end cDNA fragment was ampli®ed using 5'-AACCACGAGCTCGGGAGG-3' and 5'-GGCGAGGCCCTCAGTGGATCTC-3' primers. The 5'-and 3'-cDNA fragments contain 345 bp of overlapping region. The PCR products were puri®ed and the composite FLAG-tagged full-length wild-type and exon 2-deletion cDNAs were produced by PCR of the respective 5'-end fragments with 3'-end fragment together using the primer set: 5'-CGGGACGGACGCCGATG-3' and 5'-TCA(CTTGT-CATCGTC GTCCTTGTAGTC)GTGGATCTCGGCCTCC-GTG-3' (the bracketed sequence denotes the FLAG epitodeencoding sequence). The composite full-length cDNAs were cloned into the mammalian expression vector pcDNA3 (Invitrogen Inc.) and sequenced to con®rm the open reading frames.
